Komori
Pharma Foods International (2929) · FactLower revenue and profitLatest Financial results briefing materials (2026-09-28): "Restated"

Functional Materials business: lower revenue and profit

First written in FY2017-Q2. 17 of 32 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-09-28.

32entries
10years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2018-Q1 – FY2019AdvancedFY2022-Q3 – FY2023-Q22017: 320172018: 320182019: 420192020: 320202021: 420212022: 420222023: 320232024: 320242025: 120252026: 42026
Same theme, other companies
Functional Materials business: lower revenue and profitA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2025-H1Lower revenue and profitAnnual report

    「As a result, for the interim consolidated accounting period, revenue from the BtoB Business was ¥3,760 million, down 9.8% year on year, and segment profit was ¥709 million, down 4.6%.」

    The BtoB Business posted lower revenue and segment profit than in the year-earlier period, changing from higher revenue and profit in the previous fiscal year to lower revenue and profit.
  3. FY2024AdvancedAnnual report

    「As a result, for the fiscal year, revenue from the BtoB Business was ¥9,108 million, up 8.2% year on year, and segment profit was ¥1,573 million, up 20.9%.」

    The BtoB Business generated revenue of ¥9,108 million and segment profit of ¥1,573 million, continuing to post higher revenue and profit.
  4. FY2024-Q3AdvancedAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, revenue from the BtoB Business was ¥6,507 million, up 0.8% year on year, and segment profit was ¥1,313 million, up 22.8%.」

    The BtoB Business generated revenue of ¥6,507 million and segment profit of ¥1,313 million, continuing to post higher revenue and profit.
  5. FY2024-Q2AdvancedAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, revenue from the BtoB Business was ¥4,171 million, up 2.5% year on year, and segment profit was ¥743 million, up 6.1%.」

    The BtoB Business generated revenue of ¥4,171 million and segment profit of ¥743 million, continuing to post higher revenue and profit year on year.
  6. FY2024-Q1AdvancedAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the BtoB Business was ¥2,233 million, up 19.4% year on year, and segment profit was ¥461 million, up 22.4%.」

    The BtoB Business generated revenue of ¥2,233 million and segment profit of ¥461 million, posting higher revenue and profit year on year.
  7. FY2023Higher revenue, lower operating incomeAnnual report

    「As a result, for the fiscal year, revenue from the BtoB Business was ¥8,418 million, up 4.2% year on year, and segment profit was ¥1,301 million, down 21.6%.」

    The BtoB Business posted higher revenue, while segment profit declined 21.6% year on year.
  8. FY2023-Q2AdvancedAnnual report

    「As a result, BtoB business revenue for the six months ended in the second quarter of the current consolidated fiscal year was ¥4,071 million, up 11.6% year on year, and segment profit was ¥700 million, up 29.5% year on year.」

    Revenue and segment profit in the BtoB Business, including Meiji Pharmaceutical’s CMO, CHC and other businesses, both exceeded the year-earlier period.
  9. FY2023-Q1AdvancedAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the BtoB Business was ¥1,869 million, up 270.5% year on year, and segment profit was ¥376 million, compared with segment profit of ¥3 million in the year-earlier period.」

    The BtoB Business, including Meiji Pharmaceutical’s CMO, CHC and other businesses, expanded to revenue of ¥1,869 million and segment profit of ¥376 million.
  10. FY2022AdvancedAnnual report

    「As a result, for the fiscal year, revenue from the BtoB Business was ¥8,079 million, up 183.3% year on year, and segment profit was ¥1,660 million, up 115.6%.」

    The BtoB Business, including Meiji Pharmaceutical’s CMO and CHC businesses, expanded to revenue of ¥8,079 million and segment profit of ¥1,660 million.
  11. FY2022-Q3AdvancedAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, revenue from the BtoB Business was ¥5,696 million, compared with ¥1,927 million in the year-earlier period, up 195.5% year on year, and segment profit was ¥1,004 million, compared with ¥494 million, up 103.0%.」

    Revenue and segment profit both increased substantially in the BtoB Business, which includes Meiji Pharmaceutical, indicating business expansion following the segment reclassification.
  12. FY2022-Q2ReframedAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, revenue from the BtoB Business was ¥3,647 million, compared with ¥1,158 million in the year-earlier period, up 214.8% year on year, and segment profit was ¥541 million, compared with ¥323 million, up 67.5%.」

    The business was reorganized from the former Functional Materials Business into the BtoB Business segment, which includes Meiji Pharmaceutical. Since both revenue and segment profit in the new segment exceeded the year-earlier period, the segment change affects comparisons with historical results.
  13. FY2022-Q1Higher revenue, lower operating incomeAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the Functional Materials Business was ¥504 million, compared with ¥460 million in the year-earlier period, up 9.6% year on year, and segment profit was ¥3 million, compared with ¥106 million, down 96.6%.」

    The Functional Materials Business posted a 9.6% year-on-year increase in revenue, while segment profit declined 96.6%, resulting in higher revenue and lower profit.
  14. FY2021Full-Year Revenue Growth and Profit DeclineAnnual report

    「As a result, for the fiscal year, revenue from the Functional Materials Business was ¥2,852 million, up 10.7% year on year, and segment profit was ¥770 million, down 3.7%.」

    The Functional Materials Business posted higher full-year revenue, while segment profit declined, and the higher-revenue, lower-profit situation continues.
  15. FY2021-Q3Higher revenue, lower operating incomeAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, revenue from the Functional Materials Business was ¥1,927 million, up 1.5% year on year, and segment profit was ¥494 million, down 19.0%.」

    The Functional Materials Business posted a 1.5% year-on-year increase in revenue, while segment profit declined 19.0%, resulting in higher revenue and lower profit.
  16. FY2021-Q2AdvancedAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, revenue from the Functional Materials Business was ¥1,158 million, up 15.0% year on year, and segment profit was ¥323 million, up 13.5%.」

    The Functional Materials Business continued to post higher revenue and profit, generating revenue of ¥1,158 million and segment profit of ¥323 million.
  17. FY2021-Q1WorsenedAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the Functional Materials Business was ¥460 million, compared with ¥495 million in the year-earlier period, down 7.2% year on year, and segment profit was ¥106 million, compared with ¥149 million, down 29.0%.」

    The Functional Materials Business posted lower revenue and profit year on year, partly reflecting the backlash from concentrated shipments caused by manufacturers’ ordering timing.
  18. FY2020-Q3AdvancedAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, revenue from the Functional Materials Business was ¥1,898 million, up 54.5% year on year, and segment profit was ¥610 million, up 16.8%.」

    The Functional Materials Business generated revenue of ¥1,898 million and segment profit of ¥610 million, continuing to post higher revenue and profit year on year.
  19. FY2020-Q2Higher revenue, lower operating incomeAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, revenue from the Functional Materials Business was ¥1,007 million, up 13.2% year on year, and segment profit was ¥284 million, down 29.7%.」

    The Functional Materials Business posted a 13.2% year-on-year increase in revenue, while segment profit declined 29.7%, changing the performance profile from lower revenue and lower profit to higher revenue and lower profit.
  20. FY2020-Q1WorsenedAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the Functional Materials Business was ¥495 million, compared with ¥501 million in the year-earlier period, down 1.1% year on year, and segment profit was ¥149 million, compared with ¥239 million, down 37.6%.」

    The Functional Materials Business reported lower revenue and profit year on year, deteriorating from the higher-revenue, higher-profit trend that had continued through the previous fiscal year.
  21. FY2019AdvancedAnnual report

    「As a result, for the fiscal year, revenue from the Functional Materials Business was ¥1,777 million, up 10.5% year on year, and segment profit was ¥713 million, up 17.9%.」

    The Functional Materials Business continued to post higher revenue and profit, generating full-year revenue of ¥1,777 million and segment profit of ¥713 million.
  22. FY2019-Q3AdvancedAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, revenue from the Functional Materials Business was ¥1,229 million, up 8.5% year on year, and segment profit was ¥522 million, up 25.1%.」

    The Functional Materials Business continued to post higher revenue and profit, generating revenue of ¥1,229 million and segment profit of ¥522 million.
  23. FY2019-Q2AdvancedAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, revenue from the Functional Materials Business was ¥889 million, up 28.7% year on year, and segment profit was ¥405 million, up 86.0%, achieving substantial increases in both revenue and profit.」

    The Functional Materials Business continued to post higher revenue and profit, generating revenue of ¥889 million and segment profit of ¥405 million.
  24. FY2019-Q1AdvancedAnnual report

    「As a result, for the cumulative first quarter of the current fiscal year, revenue from the Functional Materials Business was ¥501 million, up 59.5% year on year, and segment profit was ¥239 million, up 102.3%, achieving substantial increases in both revenue and profit.」

    The Functional Materials Business continued to post higher revenue and profit, with revenue expanding to ¥501 million and segment profit to ¥239 million.
  25. FY2018-Q3AdvancedAnnual report

    「As a result, for the cumulative third quarter of the current fiscal year, consolidated revenue was ¥1,133 million, up 39.4% year on year, and segment profit was ¥338 million, up 92.7%.」

    The Functional Materials Business reported higher revenue and profit year on year, with revenue reaching ¥1,133 million and segment profit ¥338 million.
  26. FY2018-Q2AdvancedAnnual report

    「As a result, for the cumulative second quarter of the current fiscal year, consolidated revenue was ¥691 million, up 37.4% year on year, and segment profit was ¥167 million, up 86.1%.」

    The Functional Materials Business reported higher revenue and profit year on year, with revenue reaching ¥691 million and segment profit ¥167 million.
  27. FY2018-Q1AdvancedAnnual report

    「As a result, revenue from the Functional Materials Business was ¥314 million, up 40.3% year on year, and segment profit was ¥93 million, up 226.9%, representing substantial growth.」

    The Functional Materials Business reported higher revenue and profit year on year, improving from the lower-revenue, lower-profit trend through the previous quarter.
  28. FY2017-Q3RestatedAnnual report

    「As a result, revenue from the Functional Materials Business was ¥813 million, down 11.1% year on year, and segment profit was ¥175 million, down 1.4%.」

    The Functional Materials Business reported lower revenue and profit year on year, reconfirming the business’s performance trend.
  29. FY2017-Q2First statedAnnual report

    「As a result, revenue from the Functional Materials Business was ¥503 million, down 21.2% year on year, and segment profit was ¥89 million, down 29.2%.」

    The company disclosed that both revenue and segment profit in the Functional Materials Business were below the year-earlier period.
Moved together

" 적극ive efforts under the Foods with Function Claims system" moved the same way as this thread, in the same document, in 15 of its 32 moves.

151111111010★123456
  1. ★This thread
  2. 1 적극ive efforts under the Foods with Function Claims system15×
  3. 2Development of antibody therapeutics using proprietary chicken antibody technology11×
  4. 3Higher revenue and narrower loss in the biomedical business11×
  5. 4Commercialization and Development Pipeline for New Functional Materials11×
  6. 5Advertising Investment and Product Brand Expansion in Mail-Order Sales10×
  7. 6Raising Working Capital through Borrowings10×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet. It last moved in the Financial results briefing materials of 2026-09-28: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Functional Materials business: lower revenue and profit | Pharma Foods International Co.,Ltd. (2929) | Komori